Search research articles
Contact Us
Filters
Showing results (311-320 of 440) with videos related to
Page
of 44
Sort By:
Life Science Alliance
|
December 25, 2021
Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting
Chester J Joyner, Ariel M Ley, Doan C Nguyen, et al.
Blood
|
March 2, 2021
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
Vikas A Gupta, Benjamin G Barwick, Shannon M Matulis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2024
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
Pinkal Desai, Sagar Lonial, Amanda Cashen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2019
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
Sagar Lonial, Susanna Jacobus, Rafael Fonseca, et al.
Science Advances
|
September 28, 2022
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma
Aditi Sharma, Remya Nair, Abhinav Achreja, et al.
Blood
|
May 25, 2016
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z Usmani, Brendan M Weiss, Torben Plesner, et al.
British Journal of Haematology
|
May 10, 2017
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Shaji Kumar, Philippe Moreau, Parameswaran Hari, et al.
The Lancet. Haematology
|
May 30, 2020
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Saad Z Usmani, Hareth Nahi, Torben Plesner, et al.
American Journal of Hematology
|
July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events
Evangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial
Paul G Richardson, Jeff Wolf, Andrzej Jakubowiak, et al.
Page
of 44
Search research articles
Search
Showing results (311-320 of 440) with videos related to
Sort By:
Page
of 44
Life Science Alliance
|
December 25, 2021
Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting
Chester J Joyner, Ariel M Ley, Doan C Nguyen, et al.
Blood
|
March 2, 2021
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
Vikas A Gupta, Benjamin G Barwick, Shannon M Matulis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2024
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
Pinkal Desai, Sagar Lonial, Amanda Cashen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2019
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
Sagar Lonial, Susanna Jacobus, Rafael Fonseca, et al.
Science Advances
|
September 28, 2022
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma
Aditi Sharma, Remya Nair, Abhinav Achreja, et al.
Blood
|
May 25, 2016
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z Usmani, Brendan M Weiss, Torben Plesner, et al.
British Journal of Haematology
|
May 10, 2017
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Shaji Kumar, Philippe Moreau, Parameswaran Hari, et al.
The Lancet. Haematology
|
May 30, 2020
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Saad Z Usmani, Hareth Nahi, Torben Plesner, et al.
American Journal of Hematology
|
July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events
Evangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial
Paul G Richardson, Jeff Wolf, Andrzej Jakubowiak, et al.
Page
of 44